Featured Post:
Revolutionizing Prostate Cancer Detection: Dr. Heaton's Fireside Chat on the PSE Test
What if we told you there’s a game-changing method for detecting prostate cancer that’s as simple as a routine blood test?
Read PostStay In the Loop
Subscribe to receive our latest blog posts covering a wide range of topics, from groundbreaking discoveries to cutting-edge advancements and industry trends.
PREVIOUS POSTS
Unveiling Expert Insights on the PSE Test With Dr. Pohlman and Dr. Heaton
08 February 2024
2 Minutes
Time to Rethink Prostate Cancer Testing: A Q and A With OBD’s CSO, Alexandre Akoulitchev, PhD, FRSM
09 November 2023
5 Minutes
"Touchdowns for Hope”: The Montgomery Village 8U Football Team's Inspiring Journey to #BEATCANCER
27 October 2023
5 Minutes
How EpiSwitch® Blood Markers Advance Precision Medicine and Cancer Care
16 June 2023
6 Minutes
IN THE NEWS
New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies
Cancerworld | Feb 23, 2023
Scientists create ‘impressive’ new blood test for prostate cancer that is 94% accurate
The Independent | Feb 8, 2023
About Oxford BioDynamics
Oxford BioDynamics PLC (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship products are the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT predicts how a patient will respond to immune checkpoint inhibitor therapies. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.
OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring. For more information, please visit myOBDX.com.
Learn About OBD